IMMUNE ALGORITHMICS

GREAT EVENING ON 'AI in Healthcare'

28/11/2019

Promoted and streamed online worldwide and to the Austin Vita offices in Germany and the U.S., as advertised locally in Reading's giant screen at the train station, six speakers welcomed 80 attendants in an interesting evening to talk about what kind of AI and what type of ethics and responsibilities are there behind AI adoption in healthcare. Instead of only poling more positive pile to AI, the level of discussion in the event was very high and the kind of discussion we would like to see more often.

On the pictures above are our meeting ad on the giant screen followed by Dr. Hector Zenil (CEO of OIA) talk on the challenges and limitations of AI in healthcare and Dr. Kourosh Saeb-Parsy (CMO of OIA) leading the panel discussion on AI in healthcare with panelists Prof. Slawomir Nasuto, and Dr. Weizi Li from the University of Reading, and Geoff Keeling from Ethical Reading and the University of Bristol and the University Cambridge. The event was sponsored by Austin Vita and co-organised by Ethical Reading.

OXFORD IMMUNE ALGORITHMICS & AUSTIN VITA invite you to 'AI IN HEALTHCARE'

20/11/2019

Bringing people interested in closing the gap between academia and industry together, and in cutting-edge science and technology solutions, we at Oxford Immune Algorithmics with Austin Fraser and Austin Vita are organising the AI in Healthcare event.

Our Chief Medical Officer, Dr. Kourosh Saeb-Parsy, video invitation to our event
'AI in Healthcare'

At OIA we believe that automation is not about replacing humans but about scaling intelligence (machine and human) to help healthcare organisations and medical professionals to deal with real human challenges today, such as:

Improving Quality of Healthcare
Reducing Spend while Optimizing Revenue
Increase Operational Efficiencies

New technologies that harness artificial intelligence (AI) and machine learning (ML) present huge opportunities to transform healthcare, improve the quality of people, and help health professionals.

Followed by an introduction on the ‘limitations, challenges and the future of AI’ by Dr. Hector Zenil (Karolinska Institute, Karolinska Hospital and Oxford Immune Algorithmics), a panel discussion on ‘AI in healthcare’ will be moderated by Dr. Kourosh Saeb-Parsy (Reader of Transplantation at the University of Cambridge, NHS surgeon and Chief Medical Officer of Oxford Immune Algorithmics).

Our panelists are experts in the UK in the areas of healthcare and AI, from government, industry and academia. The discussion will centre around the following questions:

How can AI and ML help the NHS and its current challenges?
Is the type of AI and ML needed in clinical medicine different from other AIs?
How can AI and ML adoption be accelerated?
Who should be the direct customer of AI in healthcare today? The patient or the medical professional?
What is the future of healthcare in the next 10, 50 and 100 years?

Panelists

Dr. Kourosh Saeb-Parsy is Chief Medical Officer at Oxford Immune Algorithmics Ltd. MD & PhD in Neurosciences (Cambridge), NHS Transplant Surgeon, a University Reader & Leader of his own lab at the University of Cambridge (specialised in immunogenicity of regenerative cellular therapies) has over 15 years experience in biotech companies, director of the Cambridge In Vivo Assessment Platform & the Cambridge Biorepository for Translational Medicine.

Prof. Slawomir Nasuto is a Deputy Research Lead of the Biomedical Sciences and Biomedical Engineering Research Division within the School of Biological Sciences at the University of Reading. Prof Nasuto heads the Brain Embodiment Laboratory, an interdisciplinary facility within the School of Biological Sciences comprising two experimental laboratories performing research in Brain Computer Interfaces and cell cultures, and using complex systems science approaches to characterise the resulting data. His research on phase synchronisation, functional connectivity and complex evolving networks informs, and in turn benefits from, interrogating cognitive processes and more directly nervous system. He is interested in the use of BCI and neurofeedback for therapeutic applications and to affect human behaviour, as well as wider applications of complex systems science, swarm intelligence and machine learning to uncover complex relationships hidden within data. He published over 180 research articles in books, journals and international peer-reviewed conferences in the related areas.

Geoff Keeling is a Research Assistant at the Leverhulme Centre for the Future of Intelligence at the University of Cambridge. He is also a PhD candidate in the Philosophy Department at the University of Bristol. Geoff is interested in the ethics of artificial intelligence, and how we can make ethical decisions when we are uncertain about the consequences of our actions.
His talk examines what informed consent might look like in a future containing artificial doctors, and considers the implications for algorithmic decision-making in other areas such as finance and advertising.

Dr. Weizi (Vicky) Li, is Associate Professor of Informatics and Digital Health, Deputy Director in Informatics Research Centre, Henley Business School, University of Reading. Her research focuses on digital health, integrated system, artificial intelligence and machine learning applications in healthcare. She is a Fellow of the Chartered Institute of IT (FBCS). Her research of integrated clinical pathway system has been successfully commercialised and she has been scientific advisor of the company who provide mobile healthcare and data platform for 3000 hospitals in China. Her research impact of improving healthcare quality and efficiency using data platform and AI is recognised as one of winners of O2RB Excellence in Impact Awards in 2018, supported by University of Oxford Economic Social Research Council Impact Acceleration Account. Her research with NHS on “Applications and Implications of Machine Learning: Understanding and Predicting Healthcare Resource Usage and Patient Risk for Improved Population Engagement” has been awarded Economic Social Research Council grant in 2018. Her other research projects in healthcare are funded by private companies, NHS and Innovate UK.

Speakers

Dr. Hector Zenil is a mathematician and holds degrees in Logic (MPhil, Paris), Computer Science (PhD, Lille), & Logic & Epistemology (PhD, Paris). He has over 20 years experience in academia & industry. An authority in complexity & causality with over 100 papers published as a Senior researcher & faculty member of the University of Oxford, & as lab leader at the Karolinska Institute (awarding institution of the Nobel Prize in Medicine). He has over 100 paper in the top journals of DNA research, machine intelligence, bioinformatics, physics and complexity.

Dr Jurgen Riedel is a physicist (PhD, Germany) with interests in and contributions to classical field theory, quantum gravity, & cellular automata. Member of the board of directors of the scientific Paris-based lab LABORES & its Algorithmic Nature Group. He has over 20 years experience in Business Intelligence, data visualisation & data science working for large companies such as UBS, Citibank, Volkswagen, & Eon.

Venue
In a prime location next to Reading’s rail station at the Thames Tower (floor 12), Reading RG1 1LX (30 min from Oxford and 25 min from London's Paddington by train)

By train, the venue is literally 1 min away from Reading’s rail station. By car, you can park at the NCP rail station parking place and other parking facilities around in the city centre at a discounted (and very cheap) price after 6 PM (behind the Thames Tower building).

REGISTRATION

Please sign up for free at:
https://www.eventbrite.co.uk/e/ai-in-healthcare-tickets-79127214629
(limited to only 150 people)

The event will be streamed to the U.S. and Germany. Our CTO, Dr. Jürgen Riedel, invites the German crowd

Follow us by subscribing to our AI in healthcare newsletter at:
www.facebook.com/algocyte

OIA attending Intelligent Health UK 2020

20/11/2019

Organised in partnership with the NHSx, Intelligent Health UK is the World’s Leading AI in Medicine Summit, 5 February 2020 | London | UK

OXFORD UNIVERSITY INNOVATION SPONSORS THE PLANTING OF A TREE IN Wytham Woods IN HONOUR OF OIA'S LAUNCH

9/10/2019

OIA's first anniversary was this past September 25th and the University of Oxford planted a 4-year old beech tree in honour of Oxford Immune Algorithmics (OIA) at the Oxford University premises in Wytham Woods in Oxford where a plaque dedicated to OIA was unveiled. The tree will be taken care of for 15 years after which the plaque will be placed on the base of the tree for the hundreds of years that the tree will hopefully live and for next generations to take care. This is an initiative to create awareness and help replant an area of the woods.

Young trees like these ones can absorb CO2 much faster than larger trees as their metabolism is faster between 4 and 15 years old. Our ambitious goal at OIA for the next 15 years is to become the leaders in healthcare technology and offer an affordable scalable solution to help cure all curable human diseases. Helping plant the tree were personnel from Oxford University Innovation and OIA, including OIA's CEO Dr. Hector Zenil. OIA is honoured to have received this distinction from the 8 startups and spinouts from Oxford University that launch in average every year.

OIA Has been INVITED to pitch at bioseed 2020

6/10/2019

OIA will be at the the early stage life sciences investment event to be held at Level39 in Canary Wharf, London, January 20, 2020.

OIA ATTENDING GIANT Health Europe’s largest festival of health tech innovation

6/10/2019

On the 15-16 October 2019, OIA is attending The Global Innovation and New Technology Health Event at the Chelsea Football Club Stadium in London where it is showcased the leading health tech startups from around the world.

FURTHER validation of OIA's METHODS & algorithms

12/9/2019

An application of our research in causal models in molecular biology has been published today in one of the finest journals in molecular biology, Nucleic Acids Research (Oxford). This is the first meaningful application of algorithmic complexity to experimental cell biology beyond previous methods based on statistical approaches. It strengthens our position as pioneers in the area of causal knowledge discovery and it propels us forward as a validation of our work and technology.

Our paper shows how our methods identify DNA sequences holding key information about genetic regulation.

OPENING OF OUR NEW AI-POWERED BIOMEDICAL LAB IN A PRIME LOCATION IN READING, UK

21/8/2019

We have been growing at an exciting rate and we have moved offices three times already only this year. We have now opened our new AI-biomedical lab this month and we are already thinking of expanding it. We have here some pictures of how the the lab looks like today.

OUR NEW paper published in iscience (cell press) lays out the foundations of our technology

11/8/2019

TO BETTER DEAL WITH CAUSALITY IN MOLECULAR BIOLOGY & IMMUNOLOGY TO MAKE A REAL IMPACT IN THE FUTURE OF HEALTHCARE

This video explains in accessible terms the basic ideas behind the paper.

OIA at Turing FOUNDERS TURINGFEST in EDINBURGH

23/7/2019

We are heading to #TuringFest19 in Edinburgh this August. OIA has been invited to participate in the Turing Founders event where startups and new companies meet investors.

OIA VIP GUEST AT IN-MEMORY COMPUTING SUMMIT

30/5/2019

OIA has been invited as a VIP guest to the 3rd annual In-Memory Computing Summit Europe, on June 3 & 4, at the Park Plaza Victoria in London where we will be promoting our science and technology.

@

CONNECTing with THE LOCAL COMMUNITY IN READING

17/5/2019

We were invited to introduce OIA and present our work on AI for healthcare at the Thames Valley Artificial Intelligence meetup organised by Barclays AI Frenzy and Innovation Catalyst, University of Reading.

OIA MANIFESTO TO END ALL (PREVENTABLE) HUMAN DISEASEs, TODAY!

8/5/2019

WHAT WOULD WE DO WITH 1 BILLION DOLLARS?

At Oxford Immune Algorithmics (OIA) we firmly believe that it is our obligation to do our best to promote the use of the most advanced scientific and technological tools and methods currently available in the fight against human disease. We believe that most, if not all, diseases are curable if detected soon enough, and that current science and technology can deliver this goal not sometime in the future, but today!

Unfortunately, human priorities are often lopsided. We just saw a Hollywood movie break records last month making 1 billion USD in only a week, with some people spending as much as 500 USD, according to certain sources, for a single cinema ticket. With 1 billion USD, OIA would have been able to distribute devices to about 20 million households and equip about 100 million people with a state-of-the-art AI-based device to monitor their health, which would have given us a good shot at eradicating some of the greatest health challenges that humanity has faced, such as cancer and antibiotic resistance, which if not solved can send us back to the Middle Ages.

Written in the late 1920s, this notebook records Alexander Fleming's experiments with bacteria and antibiotics (penicillin). While medicine is driven by technology some practices haven't changed much in 100 years. Today, the same screening test in a petri dish is still used to study and diagnose antibiotic resistance. OIA is disturbing old practices with modern science and new technology to help solve some of these world challenges.

At a rate of 100 million people a week we could cover the entire world population in about a year. But even 1% of that would produce enough data and traction to significantly improve human health and probably crack cancer and other leading causes of death. That money, however, is channelled to other places, not where it may mean more and have a more lasting impact. We also know that politicians, sportsmen and actors are given extraordinary public and media attention, but not scientists, who may be losing the fight against mysticism and misinformation. We can see how even diseases that were considered under control or eradicated are making a comeback due to political regression.

Unfortunately, we can do very little to dictate or influence human priorities when it comes to what people decide to fund. However, we have assembled a small but strong team that combines decades of academy and industry experience and is capable of transforming healthcare with state-of-the-art technology and science that we have introduced and continue to develop.

WHAT CAN OIA DO TO HELP SOLVE WORLD CHALLENGES?

Current medicine relies heavily on what overburdened medical staff can do. Today, medicine can be characterised as driven mostly by what we lack: doctors’ time, patients’ data, new approved drugs, lower-cost machinery, etc. We need to change this model. More precise and quantitatively and qualitatively superior objective diagnosis and prognosis is possible, but we need to get it right, and get it done. Current machine learning (ML) methods can help, and can accurately profile diseases, and even sometimes predict patient progress and outcomes. However, some of these AI methods are often not suitable for medical purposes because they do not explain why certain specific features or markers may make sense in practice, or why a particular prediction is made instead of another. Take as an example the classification of dogs and cats. A black-box ML approach may do a perfect job but when you dig a bit further you may find that the feature separating dogs from cats according to your ML application

is that all pictures of dogs were taken outdoors, and so ML concluded that grass and clouds were the best markers for classifying dogs, getting it right 100% of the time.

While medicine is still far from using even basic AI, the lack of explanations and generative models about which features and causes drive the observed data and results may hinder the adoption of these technologies in making diagnoses and decisions based on cause and effect. This problem currently prevents scientists from understanding the true causes of natural phenomena from first principles. We seek to overcome these limits by bringing brilliant minds and machines together to cooperate in delivering a new kind of model-based AI rooted in the research we have performed at the best universities (the University of Oxford, and the Karolinska Institute--the institution that awards the Nobel Prize in Physiology or Medicine).

WANTED. VISIONARIES AND REVOLUTIONARIES BUT ONLY IF COMMITTED

We have built a small but committed team: risk takers, and doers; and we try to avoid the bluffers. At OIA we aim at understanding key health markers in a vertical fashion in order to provide each patient with their own cellular and, eventually, molecular deep temporal profile, to help us help them identify causes and effects in time for super early detection by using non-traditional model-driven machine learning suitable for medical exploration that OIA owns and continues to develop. This is how OIA plans to change medicine, healthcare, and ultimately the human condition.

We've set out on a journey to revolutionise healthcare, bringing it from the equivalent of the dial-up to fibre optics by radically enhancing the way in which data is generated, understood, and exploited. There are some different paths that may be taken, and we may sometimes get off track, but you can help us get back on track and achieve our goals faster by investing in our cause or contributing in kind, as a volunteer, or as an ambassador. If our vision resonates with yours and you share our values, you should join us and help us achieve our goals

OIA INVITED AS ACADEMIC PARTNER TO COGX IN LONDON, THE FESTIVAL OF AI AND EMERGENT TECHNOLOGIES

11/4/2019

A three day festival of events on 10-12 June, 2019.

OIA INVITED TO the global ai & big data world EXPO in london, u.k. TO DELIVER A TALK ON CAUSAL MACHINE LEARNING IN HEALTHCARE

10/3/2019

Invited by the organisers, Dr. Zenil (CEO) presented our research on AI for medicine at the World Expo on AI, Big Data & IoT at the Olympia Exhibition Centre on the 25th April in London, U.K.

Jürgen Riedel (CTO), Mariana González (Quality Manager) and Jasper Riedel attended the expo, representing OIA

we presented BEFORE MORE THAN 600 DATA GEEKS at BMW's IT centre in munich, germany

10/3/2019

We were invited to present our algorithms and novel approaches to machine learning, healthcare and personalised medicine at the Datageeks Data Day 2019 sponsored by BMW, Airbus, and AID at the impressive BMW IT Zentrum (ITZ) in Munich, Germany before a crowd of 600 people. Jürgen Riedel (CTO), and Hector Zenil (CEO) from OIA attended the conference. Hector's talk can be found on video here.

OIA's CEO and Founder, Dr. Zenil, presenting at BMW's IT headquarters in Munich, 9 March 2019

GREAT MEETING WITH OUR 1K PEOPLE MEETUP GROUP IN london, U.K.

31/1/2019

We had a successful meeting with our >1K people group in East London to explain our most recent results in Artificial Intelligence and Machine Learning, their potential to transform academia and industry including healthcare, and also their current limitations and challenges. Subscribe to our group led by Oxford Immune Algorithmics (OIA).

Drs. Jürgen Riedel and Hector Zenil from Oxford Immune Algorithmics and Mark Needham from Neo4j delivering talks on the state of AI, ML, and DL, use of network representations, challenges and limitations of technology.

NEWly PUBLISHED AND ACCEPTED PAPERS